Prolonged Maintenance with Bevacizumab (BOOST Trial) with Jacobus Pfisterer and Philipp Harter
Jan 25, 2023•32 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Professors Jacobus Pfisterer and Philipp Harter to discuss prolonged maintenance with bevacizumab. Prof. Philipp Harter is the director of the Department of Gynecology & Gynecologic Oncology at Kliniken Essen-Mitte in Essen, Germany and the chair of the AGO Study Group. Prof. Jacobus Pfisterer is Director of the Gynecologic Oncology Center in Kiel Germany and former chair of the AGO Study Group.
Highlights:
- 30-month bevacizumb maintenance does not improve progression-free survival nor overall survival in advanced ovarian cancer.
- 30-month bevacizumb maintenance is associated with more adverse events compared to 15 months.
- 15-month bevacizumb maintenance remains standard of care.
For the best experience, listen in Metacast app for iOS or Android